StonvexLoading…
StonvexStonvexStonvexCore line items from PSIX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $128.59M | $722.40M | $531.18M | $327.35M |
Operating Income | $11.39M | $109.71M | $85.47M | $57.12M |
Net Income | $7.30M | $113.99M | $97.91M | $70.29M |
EPS (Diluted) | $0.32 | $4.94 | $4.25 | $3.05 |
Total Assets | $430.68M | $424.75M | $458.95M | $437.68M |
Total Liabilities | $244.91M | $246.14M | $296.49M | $302.03M |
Cash & Equivalents | $45.09M | $41.25M | $49.05M | $49.46M |
Free Cash Flow OCF − CapEx | $17.24M | $14.14M | $21.76M | $20.04M |
Shares Outstanding | 23.05M | 23.04M | 23.04M | 23.01M |